Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02587325 · ClinicalTrials.gov registry record · Phase 1
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
A Phase 1 study, sponsored by Aadi Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02587325 is a Phase 1 study that has completed, run by Aadi Bioscience. The registered enrollment target is 15 participants.
The verdict
NCT02587325, a Phase 1 study, has completed, sponsored by Aadi Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. nab-Sirolimus (also known as ABI-009, nab-rapamycin) is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.
Interventions
- DRUG nab-sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-04-01 |
| Est. Completion | 2022-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02587325
The ClinicalTrials.gov registry entry for NCT02587325 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aadi Bioscience, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nab-sirolimus is the first listed.
NCT02587325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02587325 about?
NCT02587325 is a clinical study titled "Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension". mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. nab-Sirolimus (also known as ABI-009, nab-rapamycin) is an albumin-bound mTOR inhibitor with im...
What is the current status of trial NCT02587325?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-04-01. Estimated completion is 2022-09-16.
What interventions are being tested in trial NCT02587325?
The interventions under investigation include: nab-sirolimus (DRUG).
Who is sponsoring clinical trial NCT02587325?
This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.